The Human MHC Project aims at large-scale description of peptide-HLA binding to a wide range of HLA molecules covering all populations of the world and the accompanying generation of bioinformatics tools capable of predicting binding of any given peptide to any given HLA molecule. Here, the authors present a homogenous, proximity-based assay for detection of peptide binding to HLA class I molecules. It uses a conformation-dependent anti-HLA class I antibody, W6/32, as one tag and a biotinylated recombinant HLA class I molecule as the other tag, and a proximity-based signal is generated through the luminescent oxygen channeling immunoassay technology (abbreviated LOCI and commercialized as AlphaScreen). Compared with an enzyme-linked immunosorbent assay-based peptide-HLA class I binding assay, the LOCI assay yields virtually identical affinity measurements, although having a broader dynamic range, better signal-to-background ratios, and a higher capacity. They also describe an efficient approach to screen peptides for binding to HLA molecules. For the occasional user, this will serve as a robust, simple peptide-HLA binding assay. For the more dedicated user, it can easily be performed in a high-throughput screening mode using standard liquid handling robotics and 384-well plates. We have successfully applied this assay to more than 60 different HLA molecules, leading to more than 2 million measurements. (Journal of Biomolecular Screening 2009:173-180) 
where they control cellular immune response against viruses and other intracellular pathogens. They are highly polymorphic proteins composed of polymorphic heavy chains, α, and an invariant light chain, β2-microglobulin (β 2 m). They bind 8-to 11-amino acids long peptides derived from the cellular protein metabolism. When a peptide, β 2 m, and an MHC class I molecule engage in a productive interaction they generate a heterotrimeric complex, which is displayed at the presenting cell surface and serves as a target for peptide-specific, MHCrestricted cytotoxic T cells. If the peptide is of foreign origin the T cell may attack and lyse the target cell.
It has been shown that immunogenic peptides tend to interact with their restricting MHC molecule with an affinity better than 500 nM. 1 Being able to predict and measure the affinity of peptide-MHC binding should therefore be of considerable interest. Screening for 8-to 11-mer peptide binders-preferably from entire genomes/proteomes of microbial, as well as of self, origin-is a significant task potentially involving >10 14 peptides per polymorphic MHC molecule. This scope and complexity is further compounded by the polymorphism of the MHC system, which directly affects the specificity of peptide binding; different allelic MHC molecules may have very different peptide binding motifs. More than 1700 different human MHC (also called HLA) class I molecules have been registered (as of September 2008), and this number is still increasing. Characterizing the peptide-binding motifs and then generating peptide-binding predictors for each of these alleles, one by one, would be a major undertaking. In an attempt to cover both the peptide sequence space and the HLA polymorphism, we have chosen a strategy that integrates high-throughput biochemical analysis of peptide binding of individual HLA molecules with neural network-driven computational predictions interpolating between different HLA molecules. This strategy depends on the availability of large sets of peptide binding data covering many different HLA molecules. Thus, for our most recent update of this method, netMHCpan, 2 we employed almost 90,000 affinity determination encompassing 88 MHC/HLA molecules.
Whereas a simple and robust peptide-HLA interaction assay may be sufficient for a user interested in addressing a limited number of specific peptide-HLA interactions (say, validating peptide-HLA predictions, monitoring immune reactivity, etc.), a high-throughput peptide-HLA binding assay is essential for a user involved in large-scale T-cell epitope discovery as well as for the developer of data-intensive prediction tools. A proximity-based assay may offer all of these features-simplicity and robustness as well as high-throughput. Such assays are based upon the presence of two unique epitopes-independent and distinct from one another on the analyte. When the two epitopes are in proximity of one another, a signal can be transferred between these epitopes (and/or associated components) and subsequently relayed to an external detector. If the two epitopes are distributed on different molecules of a complex analyte, the molecular interactions leading to complex formation can be detected in solution; that is, measurements can be done while all the reactants are present (for this reason they are also denoted as "homogeneous" assays). Furthermore, proximity-based assays have the theoretical advantage that they are less prone to disturbing equilibrium and therefore better at preserving unstable interactions. They do also have some practical advantages supporting high-throughput because they do not depend upon any reactant(s) being immobilized, washed, and developed; cumbersome handling steps that otherwise are inherent to nonhomogenous assays such as the classical enzyme-linked immunosorbent assays (eLISAs).
Luminescent oxygen channeling immunoassay (LOCI, commercialized as AlphaScreen; Perkinelmer, Waltham, MA) 3, 4 is an example of a proximity-based, homogeneous assay technology. It is based on a two-bead system containing a "donor" and "acceptor" bead, each conjugated with an affinity tag directed against a unique epitope. In a typical configuration, a streptavidinconjugated donor bead is directed against a biotin-tagged reactant, whereas an antibody-conjugated acceptor bead is directed against a structure on another reactant. The signal is generated when the donor bead is excited with light at 680 nm. This causes the donor beads to convert ambient oxygen into singlet oxygen with a lifetime of about 4 µs. Within this time span it can travel approximately 200 nm in an aqueous solution. If the singlet oxygen reaches an acceptor bead before it returns to its ground state, it can activate the acceptor bead resulting in a signal at 520 to 620 nm. Because the readout has a lower wavelength (higher energy) than the excitation light source, the assay has a very low background. The LOCI technology has been compared with other assay types in different studies and has been described as a sensitive assay suited for high-throughput screening. 5, 6 It has also been compared with existing eLISA assays 7, 8 and found to be superior to eLISA with regard to speed, sensitivity, and hands-on time needed. It is a well-suited assay type for liquid handling robotics.
In this study, we describe a homogenous assay for detection of peptide binding to HLA molecules. We use it in two consecutive modes. Initially, large series of peptides at one high concentration are screened for binding and putative binders are identified. Subsequently, these are tested in concentration titrations to determine the saturation and affinity of interaction. These assays are robust and easy to conduct and are amenable to automation and high-throughput analysis. Combining bioinformatic tools with the screening and affinity assays described here, it is possible to encompass virtually the entire peptide and HLA sequence spaces.
MATERIALS AND METHODS

Peptides
Peptides were synthesized by Shafer-n (Copenhagen, denmark) by Fmoc chemistry, analyzed by high-performance liquid chromatography and mass-spectrometry, and quantitated by weight.
Recombinant HLA molecules
The recombinant HLA molecules were produced as described elsewhere. 9 In brief, the HLA molecule was generated in Escherichia coli in a version including a biotinylation substrate peptide (BSP) at the n-terminal end, which was in vivo biotinylated using a co-induced BirA enzyme and the addition of biotin during the expression. The E. coli are passed through a cell disrupter and the resulting inclusion bodies, containing the HLA protein of interest, are harvested. The HLA proteins are extracted into 8M urea and purified using ion exchange, hydrophobic, and gel filtration chromatography as described previously. The resulting denatured HLA molecules are highly active when diluted into an appropriate reaction buffer. routinely, >95% are capable of binding peptide and >95% are biotinylated. 10
Folding of peptide HLA complexes
Biotinylated recombinant HLA class I molecules were diluted from an 8M urea buffer into a mixture of peptide and recombinant human β 2 m in a tris-maleate buffer, pH 6.6, and added to a polypropylene 384-well plate (nunc, roskilde, denmark) using a liquid handling robot (Microlab Star; Hamilton robotics, reno, nV). The HLA concentrations ranged from 0.5 to 5 nM, and β 2 m concentration ranged from 7.5 to 200 nM. For screening, the peptide concentration was 5 µM. For concentration titrations, 11 five-fold dilutions spanning from 66.6 µM to 0.01 nM were tested. The reaction mixtures were incubated for 48 h at 18 °C to allow for peptide-HLA complex formation reaching steady state.
Antibodies
The conformation-dependent and pan-specific anti-HLA class I mouse monoclonal antibody, W6/32, 11 was produced in vitro from hybridoma cell lines (Integra, Chur, Switzerland) and purified by ion exchange chromatography. Peroxidase-labeled anti-human β 2 m polyclonal rabbit serum, P0174, and peroxidase-labeled dextran polymer conjugated to anti-rabbit IgG goat serum, enVision 1 , was from dako (Glostrup, denmark; #P0174 and #K4003, respectively).
LOCI (AlphaScreen) assay
The donor and acceptor beads of the LOCI assay were from Perkinelmer (Shelton, CT). donor beads were obtained preconjugated with streptavidin; acceptor beads were in-house conjugated with W6/32 using standard procedures as described by the manufacturer, except that the antibody concentration was increased to 1 mg/ml during conjugation. The assay was conducted in phosphate-buffered saline (PBS) with 0.1% Lutrol  F-68 as surfactant; 15 µl of the folding mixture was transferred to a 384-well Optiplate (Perkinelmer) followed by addition of 15 µl of a solution containing W6/32 acceptor beads and streptavidin donor beads (final concentration of beads was 5 µg/ml). The plates were incubated O/n at 18 °C. To ensure temperature equilibrium during the relative long reading time (5 min per plate) plates were placed next to the reader (enVision™, Perkinelmer) 1 h prior to reading. All handling of LOCI reagents was done in the dark or in green light. Liquid handling in 384 plates was performed with robotics (Microlab Star, Hamilton robotics).
ELISA assay
The eLISA assay was performed as described earlier. 12 In brief, W6/32-coated, 384-well MaxiSorp plates (nunc) were blocked with PBS, 5% skimmed milk powder. Peptide-HLA complexes were added and incubated O/n at 4 °C. Plates were washed to remove unbound HLA, and bound HLA molecules were detected with P0174 for 1 h at 4 °C then washed. To amplify the signal a secondary antibody, enVision  , was added for 30 min at room temperature followed by a final washing step. Plates were developed with tetramethylbenzidine (TMB) for 30 min, stopped with 0.3 M sulfuric acid, and read on a BioTek PowerWave™ HT Microplate reader (BioTek Instruments, Inc., Winooski, VT) at 450 nm.
Data analysis
Assay signals (cps or Od 450) were converted to peptide-HLA complex concentration using a peptide-HLA standard curve. Peptide affinity (K d ) was calculated using Prism  software (GraphPad Software, Inc., San diego, CA). Z′ was calculated as described in the study by Zhang and colleagues. 13 
RESULTS
The LOCI assay was based on commercially available streptavidin donor beads used to capture the biotinylated HLA molecule and commercially available acceptor beads in-house conjugated with the monoclonal antibody W6/32, which recognizes the trimeric complex of HLA, β 2 m, and peptide. A schematic view of the LOCI assay setup is outlined in Figure 1 . A series of pilot experiments was performed to adjust and optimize the assay conditions. Initially, the concentrations of the reactants, HLA, β 2 m, and peptide, were adapted to the LOCI system, seeking to adjust the reaction to exhibit maximum peptide sensitivity, that is, no complex formation in the absence of peptide and efficient complex formation in the presence of relevant peptide. The first parameter addressed was the HLA concentration. Biotinylated HLA (in casu HLA-B*0702) was titrated into a reaction mixture containing a fixed excess concentration (300 nM) of β 2 m and either a fixed excess concentration (5000 nM) of binding peptide or no peptide ( Fig. 2A) . The LOCI assay was highly reproducible and duplicate measurements gave low standard deviations. Thus, reliable signals could be detected already at 0.1 nM, and in this setup peak signals were reached at HLA concentrations around 10 nM. note, the nonspecific signal (i.e., when no binding peptide is added) is very low and does not give any signal below 10 nM HLA. note also, that at HLA concentrations above 20 nM, the specific signal is fading probably due to saturation of the system. This phenomenon is well known in LOCI assays and is termed hooking. For further studies, we selected 1.25 nM HLA because this receptor concentration gave a signal at ~40000 cps, well below the max capacity of the system and still on the linear part of the concentration-response curve of the specific signal. next, the concentration of β 2 m was titrated into a reaction mixture containing a fixed concentration (1.25 nM) of biotinylated HLA-B*0702 and either a fixed excess concentration (5000 nM) of binding peptide or no peptide (Fig. 2B) . even 1 nM β 2 m generated specific peptide binding, and this increased almost linearly up to 100 nM of β 2 m, whereas further increases in β 2 m up to 1000 nM appeared to saturate the HLA. note that the nonspecific signal was very low even at 1000 nM β 2 m. For further studies, we selected to use between 10 and 100 nM β 2 m depending upon the HLA molecule being examined. Finally, the generation of a peptide-dependent signal was tested. The concentration of peptide was titrated in duplicate into a reaction mixture containing fixed concentrations of biotinylated HLA and β 2 m (in casu 1.25 nM HLA-B*0702 and 100 nM β 2 m). Again, the signals obtained were highly reproducible, that is, low standard deviations. Three peptides with different affinities for HLA-B*0702 were tested. In all three cases, sigmoid semilogarithmic dose-response curves were obtained ( Fig. 3) and could be analyzed by curve-fitting programs such as GraphPad Prism. As judged by the signal in cps, the most potent binder of these three peptides half-saturated the HLA around 3 nM, the intermediate binder around 170 nM, and the least potent binder around 725 nM. In all cases, the HLA appeared saturable, although the level of saturation depended upon the identity of the peptide and resulting affinity for the HLA in question. We then analyzed 93 peptides (45 peptides on HLA-B*0702, 30 peptides on HLA-B*0801, and 18 peptides on HLA-B*3901) for binding using both the new LOCI-based assay and, as a correlation, a previously reported eLISA assay. The affinities of the peptides ranged from 0.2 to 10000 nM, and throughout the entire range, the affinities obtained with the two assays gave similar results. Comparing the logarithm of the binding affinities obtained with the two assays ( Fig. 4) showed a very high degree of correlation (R 2 = 0.96), and the observed regression line, K d (eLISA) = 0.85*K d (LOCI) + 0.31, was very close to the expected regression line, K d (eLISA) = K d (LOCI). The latter would suggest that at affinities below 100 nM, the LOCI assay yielded slightly lower (i.e., better) affinity measurements than the eLISA-based assay.
Sensitivity, dynamic range, and signal-to-background ratio
using purified peptide-HLA complexes, the sensitivity of the LOCI-based assay was compared with that of the eLISAbased assay (Fig. 5) . The LOCI-based assay was slightly more sensitive (detection limit, 1 pM peptide-HLA complex) than that of an enVision  (dako) amplified eLISA-based assay (detection limit, 4 pM peptide-HLA complex), which was better than that of an unamplified eLISA assay (detection limit, 16 pM peptide-HLA complex). note that the standard deviations were smaller for the LOCI assay compared with the eLISA assay. The dynamic range of the LOCI-based assay was larger (ranged from 1 pM to 1000 pM) than the dynamic range of the enVision  -amplified eLISA (ranged from 4 pM to 500 pM). note that these results were obtained with 5 µg/ml bead concentrations. It should be possible to obtain an even larger dynamic range of the LOCI assay if one were to use the higher concentration of beads recommended by the manufacturer. 2
FIG. 1.
Schematic diagram of the LOCI assay setup with streptavidin donor beads and the monoclonal antibody W6/32 conjugated to acceptor beads. The HLA molecule is biotinylated during fermentation at an n-terminal BSP site. The epitope for W6/32 is formed when the HLA molecule forms a trimeric complex with a peptide and β 2 m. In the presence of an HLA binding peptide the acceptor bead is brought into close proximity of the donor bead and a signal can be measured. LOCI, luminescent oxygen channeling immunoassay; BSP, biotinylation substrate peptide. High-affinity binding peptides were used to establish signal strength; nonbinders (or no peptide added) were used to establish background. For both the eLISA and LOCI assays, signal-tobackground (S/B) ratios were calculated for a large cohort of HLA molecules (Table) . In all cases, the LOCI-based assay had a much better S/B ratio than the eLISA-based assay, with improvements ranging from 3-to 10-fold (average, 7-fold). For some HLA molecules, exemplified by the A24 supertype members HLA-A*2301 and HLA-A*2403 where the eLISA-based assay was barely operational with S/B ratios at ~3 and Z′ at ~0.20, the LOCI-based assay gave robust and reliable readings with S/B ratios at ~10 and a Z′ at ~0.71.
Screening for HLA binders
A rational setup strategy is essential when conducting largescale screenings, which potentially could entail 10,000s of peptides. Preliminary experiments suggested that a single peptide concentration of 5000 nM would be a suitable screening concentration allowing differentiation between binders and nonbinders. We speculated whether peptides, which did not give a sufficient signal at this concentration, could be deemed to have a poorer affinity (higher K d ) than 5000 nM, and therefore be characterized as a nonbinder; that is, no further experimentation would be necessary. In contrast, peptides giving a sufficient signal might qualify for a full peptide titration determining the affinity. We selected 93 peptides predicted to be binders to the A1 supertype member, HLA-A*2501, and tested their binding to three different HLA alleles (two A1 supertype members, HLA-A*2501 and -A*8001, and one B7 supertype member, HLA-B*0702). For testing, we used both a single peptide concentration of 5000 nM (the "screening procedure") and a full peptide titration (the "affinity procedure") ( Fig. 6A-C, closed  symbols) . In addition, known binding peptides were included to allow a positive screening signal to be evaluated ( Fig. 6A-C , open symbols). Graphs were made to evaluate whether there is a useful relationship between the screening value and the actual affinity (Fig. 6) . Two thresholds are indicated: an affinity threshold of 5000 nM (the vertical line), which separates peptides designated as nonbinders (>5000 nM) from those whose affinity should be determined in more detail, and a screening threshold of one-third of the positive screening signal obtained (the horizontal line). For all three peptide-HLA combinations, the vast majority of peptides were found in the upper left quadrant (positive in both screening and affinity measurements; the "true positives") or in the lower right quadrant (negative in both screening and affinity measurements; the "true negatives"). The accuracies, the sum of the true positives and negatives, were 97%, 84%, and 96% for HLA-A*2501, -A*8001, and -B*0702, respectively. Between 0% and 1% of the peptides fell into the false negative category (the lower left quadrant); those are the peptides that inadvertently will be assigned nonbinders despite having a binding affinity better than 5000 nM when thoroughly examined. Between 3% and 16% fell into the false positive category (the upper right quadrant); those are the peptides that would be extensively tested despite being nonbinders, and in the end will be correctly assigned. Thus, the screening procedure will save considerable resources at the expense of a very modest loss in data accuracy.
DISCUSSION
Here, we present a peptide-HLA class I binding assay that can be used in a screening procedure for identifying peptides binding to HLA molecules and in a titration procedure for determining the affinity of the positive peptides from the screening by using the homogenous assay platform LOCI™. The assay is well suited for high-throughput analysis by liquid handling robotics and applies to a wide range of HLA alleles.
We have compared this assay with an existing eLISA assay qualitatively and quantitatively. We find that peptide binding affinities measured in the LOCI assay correlate very well with affinities measured in the eLISA assay. The LOCI assay was more sensitive and had a broader dynamic range than the eLISA assay (1 to 1000 pM vs 4 to 500 pM). The LOCI assay was found to improve the S/B ratio significantly compared with the eLISA assay. The increased S/B-ratio made it possible to analyze alleles that had too high of a background in the eLISA assay.
even though the LOCI technology is superior to eLISA with regard to dynamic range and sensitivity, there are some issues that need to be taken into account, and optimized, when developing assays. An important concern is assay sensitivity. In our experience, the antibody concentration on the acceptor beads can be manipulated to give higher assay sensitivity at higher antibody density, or lower sensitivity at lower antibody density. Also the signal generated in the LOCI system is very temperature sensitive; a sample will give a lower signal at 4 °C than at 25 °C. The reader should be in a temperature-controlled location and samples allowed to equilibrate to this temperature before reading. Other concerns must also be considered, such as the use of any color reagent in the assay, especially red (absorbing at 520 to 680 nm), which will absorb the signal from the acceptor beads, or the laser; or the use of reducing agents such as azide, which will quench the singlet oxygen released by the donor beads.
Another important issue is the costs of running the assay. By increasing the antibody concentration during conjugation of the acceptor beads, we were able to use fewer beads, 5 µg/ml, making the operating cost of the LOCI assay equivalent to the eLISA. The real cost-saving feature of the LOCI assay lies in its homogeneous design. The development of the eLISA assay involves coating, blocking, capture of complex, primary and secondary detection, substrate development reaction and stopping, not to mention multiple washing steps. All these operations are reduced to one step in the LOCI assay-add the beads. In a high-throughput setup, numerous assays are run and the simplicity of the LOCI assay liberates resources, which can be allocated elsewhere in the laboratory, or used to increase throughput. In the setup used in our laboratory the LOCI assay has reduced operation cost in terms of manpower by at least 60%. Many different assays to measure peptide-MHC interactions have been suggested over the years, yet, there is no generally accepted standard method available. We have recently generated preoxidized recombinant MHC class I molecules (MHC-I), which can be purified to homogeneity under denaturing conditions (i.e., in the absence of any contaminating peptides). Such denatured MHC-I molecules are functional equivalents of "empty molecules." When diluted into aqueous buffer containing β 2 m and appropriate peptide, they fold rapidly and efficiently in an entirely peptide-dependent manner. Here, we exploit the availability of these molecules to generate a quantitative LOCI-based assay capable of measuring the affinity of the interaction between peptide and MHC-I. In the screening procedure, only one peptide concentration (5 µM) is analyzed and we show that we can identify binding peptides based on this single measurement by setting a cutoff based on a high-affinity control peptide. The peptides used to validate this procedure were all predicted to bind to the HLA-A*2501 allele according to the netMHCPan predictor. 2 not surprisingly, 82% of these peptides actually bound to this allele (Fig. 6A) . HLA-A*8001, an allele belonging to the same supertype as HLA-A*2501 and therefore of comparable binding characteristics, bound 32% of the same peptides. In contrast, HLA-B*0702, which belongs to a different supertype with different binding characteristics, only bound 16% of the peptides. Primarily, we would like to avoid making false negative calls. Obviously, we would also like to avoid making false positive calls; however, this is more a question of practicality and economy; eventually the correct result will be obtained. note that for the testing of HLA-A*2501 predicted binders on HLA-B*0702-a situation that resembles a random screening with a very low binding expectancy-further efforts could be stopped for 81% of the peptides, leading to considerable savings in time and resources at the expense of only one missed binder. Of the remaining 19% peptides, 84% were indeed binders. In a situation where peptides are predicted to bind, one might consider whether it is worthwhile to do a screening, inasmuch as ~85 % of the predicted binding turns out positive and you may as well go straight to the titration procedure. However, for a peptide that is not predicted to bind, the screening procedure is a good tool to identify potential binders from a large pool of peptides. It cannot be ruled out that we will miss potential binders, but really interesting peptides (K d < 500 nM) are unlikely not to be identified by the screening procedure. Thus, using this assay and the strategy described here, it is possible to perform a rational screening for peptide-HLA binders. This assay is simple and sensitive, and one can envision that the necessary reagents, standards, and protocols can be made available to the scientific community.
